§ Federal grant opportunity · RFA-AG-26-023
Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine
National Institutes of Health is accepting applications for Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine. The deadline is Rolling / not published and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- Rolling / not published
- Award range
- Award amount not published
- Eligibility
- state governments, county governments, city or township governments, for profit organizations other than small businesses, independent school districts, private institutions of higher education, public and state institutions of higher education, other, public and indian housing authorities, other native american tribal organizations, nonprofits non higher education with 501c3, nonprofits non higher education without 501c3, federally recognized native american tribal governments, small businesses, special district governments
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- RFA-AG-26-023
Program overview
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose a program that supports integrative, cross-disciplinary projects aimed at scaling up mechanistic studies to understand the genomic underpinnings of the pathogenesis and progression AD/ADRD. The proposed research projects will employ interdisciplinary approaches that integrate innovative techniques to dissect the genomic drivers of AD/ADRD. These projects will leverage advanced analytical methods, including machine learning and comparative genomic analysis across multiple genetic ancestries or multiple neurodegenerative diseases, along with cutting-edge tools like genome editing, functional characterization assays, and emerging single-cell and spatial omics technologies. These studies will use sophisticated disease models, such as human stem cell-based systems, ex vivo, and in vivo models that reflect different genetic ancestries, various model organisms, or multiple neurodegenerative conditions. These cross-ancestry, cross-disease, and cross-species approaches will enable a more comprehensive investigation of the genomic drivers of neurodegeneration and neuropathogenesis. Ultimately, this initiative may lead to the identification of actionable therapeutic targets for AD/ADRD, meeting the urgent need for mechanism-driven insights that can guide precision medicine approaches for its treatment. Applications are not being solicited at this time. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the U01 activity code. Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this new NOFO.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before Rolling / not published, allowing time for registration and validation.
Related grant opportunities
- Controlled Clinical Trials on Long-Term Effects of Nutritional Interventions on the Progression of Risk Factors for Age-Related Chronic Conditions Over the Life Span and Their Age of Onset
- Understanding Cerebellar Contributions to Cognitive and Affective Functions in Aging and Alzheimer's Disease/Alzheimer's Disease-Related Dementias
- Autism Centers of Excellence R01
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative Research on Behavior at the Organismal Level
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.